| Titre : | The clinical and economic impact of three-monthly long-acting formulation of paliperidone palmitate versus the one-monthly formulation in the treatment of schizophrenia in France : a cost-utility study (2019) |
| Auteurs : | ARTEGA DUARTE C ; FAKRA ERIC ; VAN GILS C ; GUILLON P |
| Type de document : | Article |
| Dans : | ENCEPHALE (6 vol 45, 2019) |
| Article en page(s) : | 459-467 |
| Descripteurs |
[SANTEPSY] ETUDE DE COHORTE [SANTEPSY] SCHIZOPHRENIE |
| Résumé : | Schizophrenia entails a considerable humanistic and economic burden. Improved treatment continuity to antipsychotic therapy is paramount to reduce the risk of relapse. The novel three-monthly paliperidone palmitate treatment (PP3M) offers the longest dosing interval currently available in France. This study assesses its cost-effectiveness, versus the currently available one-monthly long-acting treatment (PP1M) in French schizophrenic patients.With slightly better QALY outcomes and a cost-saving effect when compared to PP1M, introducing PP3M is an improvement to the current treatment in France. [extrait du résumé d'auteur] |
| En ligne : | https://www.em-premium.com/article/1335428 |
Bibliothèque Médicale et Professionnelle
Bibliothèque Médicale & Professionnelle
Accueil
Sélection de la langue
Se connecter
Adresse
Bibliothèque Médicale et Professionnelle04 74 52 28 07
contact
